Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Assist. Prof. Dr. Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Guilan University of Medical Sciences | Iran

Dr. Majid Taati Moghadam is a dedicated Medical Microbiologist and Antimicrobial Resistance Researcher based in Rasht, Iran. He specializes in microbial pathogenesis, antibiotic resistance mechanisms, bacteriophage therapy, and the connection between microbiota and neurodegenerative disorders. His multidisciplinary expertise extends across clinical microbiology, infectious disease prevention, and translational therapeutics, making him a leading figure in Iran’s microbiological research community.

Professional Profile

Scopus

Google Scholar

ORCID

Education

Dr. Majid Taati holds a Ph.D. in Medical Bacteriology from Iran University of Medical Sciences (2017–2022), where his research investigated the relationship between oral microbiome shifts and Alzheimer’s disease. He earned his Master’s degree in Medical Microbiology from Kerman University of Medical Sciences (2012–2015), focusing on carbapenem resistance genes in Klebsiella pneumoniae. His academic journey began with a Bachelor’s degree in Microbiology from Islamic Azad University, Lahijan Branch (2007–2012). Throughout his studies, he demonstrated a keen interest in antibiotic resistance, clinical diagnostics, and the molecular biology of pathogens.

Experience

Dr. Majid Taati has played key roles in over a dozen microbiological research projects across Iran. As both a principal investigator and main collaborator, he has contributed to studies on extended-spectrum beta-lactamase (ESBL) genes, resistance enzymes in E. coli, and the antimicrobial effects of plant extracts like Ephedra pachyclada. He has worked extensively on projects involving nosocomial infections, multidrug-resistant bacteria, and genetic analysis methods such as MLVA and HRM techniques. He also authored the textbook Essential Medical Microbiology in Persian, and presented his findings at several major Iranian congresses, including the International Microbiology Congress. His laboratory and academic experience bridges both applied research and educational leadership.

Research Interests

Dr. Majid Taati research focuses on antimicrobial resistance mechanisms, phage and endolysin therapy, bacterial biofilm inhibition, and engineered phage enzymes for resistant infections. He is also deeply involved in exploring the role of microbiota in neurological and neuropsychiatric disorders, especially Alzheimer’s disease. His studies aim to bridge clinical microbiology with therapeutic innovation addressing global health threats posed by superbugs like carbapenem- and colistin-resistant Gram-negative bacteria. His recent projects extend to wound healing biomaterials, phage protein therapies, and microbiome-based diagnostics, reflecting his broad and multidisciplinary scientific interests.

Awards

Recognized for his extensive research contributions, Dr. Majid Taati is a deserving nominee for the “Best Researcher Award” in medical microbiology and antimicrobial resistance. His scholarly excellence, particularly in phage therapy and resistance gene profiling, aligns well with the objectives of scientific bodies that honor groundbreaking research. With dozens of publications in top-tier journals and continuous involvement in nationally significant projects, he exemplifies leadership in translational microbiology and global infectious disease research.

Publications

  • Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
    Year: 2020
    Citations: 316

  • Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review
    Year: 2020
    Citations: 311

  • How phages overcome the challenges of drug resistant bacteria in clinical infections
    Year: 2020
    Citations: 173

  • Bacteriophages, a new therapeutic solution for inhibiting multidrug-resistant bacteria causing wound infection: lesson from animal models and clinical trials
    Year: 2020
    Citations: 125

  • COVID-19 (Coronavirus disease 2019): a new coronavirus disease
    Year: 2020
    Citations: 108

  • Evaluation of Nano-curcumin effects on expression levels of virulence genes and biofilm production of multidrug-resistant Pseudomonas aeruginosa isolated from clinical samples
    Year: 2019
    Citations: 108

  • Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant gram-negative bacteria
    Year: 2021
    Citations: 58

Conclusion

Dr. Majid Taati Moghaddam Ziabari has built an impressive career defined by scientific innovation, deep academic rigor, and a commitment to combating infectious diseases. His pioneering work in bacteriophage therapy and antimicrobial resistance not only advances microbiological science but also addresses some of the most urgent global health challenges. With his rich publication record, research leadership, and academic influence, he is a prime candidate for international recognition, especially the Best Researcher Award. His career serves as a model of excellence in translational research and academic impact.

Yun zou | Microbiology | Best Researcher Award

Mr. Yun zou | Microbiology | Best Researcher Award

The General Hospital of Western Theater Command | China

Zou Xinyun is a Master’s degree candidate and Chief Technician with a strong background in oncology and biomedical engineering. Since graduating from Hubei University of Science and Technology in 2011, he has been dedicated to medical research and clinical practice at the General Hospital of the Western Theater Command of the Chinese People’s Liberation Army. Currently, he is pursuing his Master’s degree in Biomedical Engineering at the School of Medicine, Southwest Jiaotong University, under the guidance of Professor Zhang Ling. His research contributions have been recognized through multiple prestigious awards and numerous scientific publications.

Profile👤

ORCID

Strengths for the Awards✨

  • Extensive Research Contributions 📚

    • Zou Xinyun has published five SCI papers as the first author in reputable journals, including Translational Cancer Research, Discover Oncology, and Clinical and Experimental Hypertension.
    • He has also co-authored several other publications, demonstrating his active involvement in collaborative research.
  • Academic Excellence & Recognition 🎓

    • He is a National Graduate Scholarship recipient, which highlights his academic excellence and dedication to research.
    • Recognized as an Outstanding Graduate of Hubei University of Science and Technology and an Excellent Medical Worker at his hospital, indicating his exceptional contributions to both research and clinical practice.
  • Strong Clinical and Research Background 🏥

    • With over a decade of experience at the Department of Oncology in a leading military hospital, he has gained deep expertise in clinical oncology research.
    • His ongoing Master’s in Biomedical Engineering at Southwest Jiaotong University under Professor Zhang Ling demonstrates a strong interdisciplinary approach to cancer research.
  • Zou Xinyun has an impressive research profile, particularly in oncology and biomedical engineering, with multiple SCI-indexed publications, academic excellence awards, and clinical research experience. While he is a strong candidate for the Best Researcher Award, focusing on high-impact publications, independent funding, and broader collaborations could further solidify his position as a top-tier researcher in his field.

🎓 Education

  • Bachelor’s Degree (2011) – Hubei University of Science and Technology
  • Master’s Degree Candidate (2021–2024) – School of Medicine, Southwest Jiaotong University
    • Research supervised by Professor Zhang Ling
    • Specializing in Biomedical Engineering

🏥 Experience

  • 2011–Present: Chief Technician, Department of Oncology, General Hospital of the Western Theater Command, Chinese People’s Liberation Army
    • Over a decade of experience in oncology research and clinical applications
    • Involved in advanced medical diagnostics and cancer treatment strategies

🔬 Research Interests On Microbiology

Zou Xinyun’s research focuses on oncology, biomedical engineering, and clinical cancer treatment. His work explores innovative approaches in cancer diagnostics, therapeutic interventions, and biomedical applications to improve patient outcomes. He is particularly interested in translational cancer research and the development of novel treatment methodologies.

🏆 Awards & Honors

  • 🏅 Outstanding Graduate – Hubei University of Science and Technology
  • 🏅 Excellent Medical Worker – General Hospital of the Western Theater Command
  • 🏅 National Graduate Scholarship – Recognized for academic excellence and research contributions

📚 Publications

  • Title: Association between immune cells and endometrial cancer: A bidirectional Mendelian randomization study

    • Authors: Xinyun Zou, Jinlan Shen, Hengdi Zhang, Fangyuan Kong, Xuemei Jin, Ling Zhang
    • Year: 2024
    • Citations: Not provided
  • Title: The causal effects of immune cells on pancreatic cancer: A 2‑sample Mendelian randomization study

    • Authors: Zou X, Shen J, Yong X, Diao Y, Ling Zhang
    • Year: 2024
    • Citations: Not provided
  • Title: Emodin ameliorates myocardial fibrosis in mice by inactivating the ROS/PI3K/Akt/mTOR axis

    • Authors: Huang W, Zhou P, Zou X, Liu Y, Zhou L, Zhang Y
    • Year: 2024
    • Citations: Not provided
  • Title: Radiomics in Nasopharyngeal Carcinoma

    • Authors: Wenyue Duan, Xiong B, Tian T, Zou X, He Z, Ling Zhang
    • Year: 2022
    • Citations: Not provided

🔚 Conclusion

Zou Xinyun is a dedicated researcher and medical professional with a strong commitment to oncology and biomedical engineering. His contributions to cancer research, coupled with his clinical expertise, have earned him significant recognition in the medical field. With a solid track record of academic excellence, professional experience, and impactful publications, he continues to advance medical science and improve patient care.